Myricetin could be a potential radiosensitizer for lung cancer therapy. - GreenMedInfo Summary
Enhancement of recombinant myricetin on the radiosensitivity of lung cancer A549 and H1299 cells.
Diagn Pathol. 2014 Mar 20 ;9:68. Epub 2014 Mar 20. PMID: 24650056
OBJECTIVE: Myricetin, a common dietary flavonoid is widely distributed in fruits and vegetables, and is used as a health food supplement based on its immune function, anti-oxidation, anti-tumor, and anti-inflammatory properties. The aim of this study was to investigate the effects of myricetin on combination with radiotherapy enhance radiosensitivity of lung cancer A549 and H1299 cells.
METHODS: A549 cells and H1299 cells were exposed to X-ray with or without myricetin treatment. Colony formation assays, CCK-8 assay, flow cytometry and Caspase-3 level detection were used to evaluate the radiosensitization activity of myricetin on cell proliferation and apoptosis in vitro. Nude mouse tumor xenograft model was built to assessed radiosensitization effect of myricetin in vivo.
RESULTS: Compared with the exposed group without myricetin treatment, the groups treated with myricetin showed significantly suppressed cell surviving fraction and proliferation, increased the cell apoptosis and increased Caspase-3 protein expression after X-ray exposure in vitro. And in vivo assay, growth speed of tumor xenografts was significantly decreased in irradiated mice treated with myricetin.
CONCLUSIONS: The study demonstrated both in vitro and in vivo evidence that combination of myricetin with radiotherapy can enhance tumor radiosensitivity of pulmonary carcinoma A549 and H1299 cells, and myricetin could be a potential radiosensitizer for lung cancer therapy.
VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: https://www.diagnosticpathology.diagnomx.eu/vs/5791518001210633.